US20190175726A1 - Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response - Google Patents

Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response Download PDF

Info

Publication number
US20190175726A1
US20190175726A1 US16/274,466 US201916274466A US2019175726A1 US 20190175726 A1 US20190175726 A1 US 20190175726A1 US 201916274466 A US201916274466 A US 201916274466A US 2019175726 A1 US2019175726 A1 US 2019175726A1
Authority
US
United States
Prior art keywords
protein
human lag
derivative
imp321
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US16/274,466
Other versions
US11583582B2 (en
Inventor
Frederic Triebel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immutep SAS
Original Assignee
Immutep SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immutep SAS filed Critical Immutep SAS
Priority to US16/274,466 priority Critical patent/US11583582B2/en
Publication of US20190175726A1 publication Critical patent/US20190175726A1/en
Priority to US18/098,199 priority patent/US20230149541A1/en
Application granted granted Critical
Publication of US11583582B2 publication Critical patent/US11583582B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Definitions

  • the present invention relates to the use of recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response.
  • brackets [ ] refer to the attached reference list.
  • the lymphocyte activation gene 3 (hlag-3) expressed in human CD4 + and CD8 + activated T cells as well as in activated NK cells encodes a 503 amino acids type I membrane protein (LAG-3) with four extracellular immunoglobulin superfamily (IgSF) domains [1].
  • a murine lymphocyte activation gene 3 (mlag-3) was cloned and approximately 70% of homology was found with hlag-3, with the same proline rich motif in the intracytoplasmic tail.
  • LAG-3 (CD223), described as being a natural high affinity ligand for MHC class II, is known to induce maturation of monocyte-derived dendritic cells in vitro, and is used as an immunotherapy adjuvant to induce CD4 T helper type 1 responses and CD8 T cell responses in vivo [2]. Further information regarding LAG-3 and its use as an immunostimulant may be found in TRIEBEL et al. [1], TRIEBEL et al. [3], and HUARD et al. [4].
  • soluble LAG-3 can bind to MHC class II molecules and can induce dendritic cells to mature and migrate to secondary lymphoid organs where they can prime na ⁇ ve CD4-helper and CD8-cytotoxic T cells leading to tumour rejection [5].
  • IMP321 recombinant soluble human LAG-3Ig fusion protein
  • Monocytes are produced by the bone marrow from haematopoietic stem cell precursors called monoblasts. They constitute between three to eight percent of the leukocytes in the blood. Monocytes circulate in the bloodstream for about 24 hours (half-life of 8 hours) and then typically move into tissues throughout the body. In the tissues, monocytes mature into macrophages, epithelioid cells or antigen-presenting cells (APCs, for example dendritic cells). Monocytes are responsible for phagocytosis (ingestion) of foreign substances in the body.
  • APCs antigen-presenting cells
  • Monocytes can perform phagocytosis using intermediary (opsonising) proteins such as antibodies or complement that coat the pathogen, as well as by binding to the pathogen directly via pattern-recognition receptors that recognize pathogens. Monocytes are also capable of killing infected host cells via antibody, termed antibody-dependent cell-mediated cytotoxicity (ADCC). Due to their secretion and phagocytosis properties, monocytes-macrophages occur in aspecific and specific immune response.
  • intermediary proteins such as antibodies or complement that coat the pathogen, as well as by binding to the pathogen directly via pattern-recognition receptors that recognize pathogens.
  • Monocytes are also capable of killing infected host cells via antibody, termed antibody-dependent cell-mediated cytotoxicity (ADCC). Due to their secretion and phagocytosis properties, monocytes-macrophages occur in aspecific and specific immune response.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • Said induced immunity manifests itself by a significant increase in blood monocyte counts.
  • monocytes are end-of-differenciation hematopoietic cells and can not proliferate. They can stay in the blood as monocytes or differentiate toward either macrophages or dendritic cells under the influence of different cytokines, until they die.
  • the mechanism of action involved may be a proliferative signal directed to hematopoietic precursor cells (before the promonocyte stage) residing in the bone marrow, or an increase in the half-life or residence time of mature circulating monocytes.
  • the present invention relates to the use of a recombinant LAG-3 protein or derivative thereof that elicits monocyte mediated immune response, for the manufacture of a medicament inducing an increase in monocyte numbers for the treatment of an infectious disease or cancer.
  • LAG-3 in the sense of the present invention, is meant mutants, variants and fragments of LAG-3 provided that they maintain the ability of LAG-3 to bind MHC class II molecules.
  • LAG-3 may be used:
  • an effective plurality of doses of a recombinant LAG-3 protein or derivative thereof in the sense of the present invention, is meant a formulation that allows administration of one dose of a recombinant LAG-3 protein or derivative thereof every one to several weeks for at least 12 weeks, and preferably for at least 24 weeks, separated by 13-day ⁇ 2 days administration-free intervals.
  • the administration is an every-two-week schedule.
  • one dose of a recombinant LAG-3 protein or derivative thereof in the sense of the present invention, is meant a formulation that allows one administration in the range of 0.25-30 mg, preferably 1-6.25 mg, more preferably 6-30 mg, and for example about 1.25 mg of recombinant LAG-3 protein or derivative thereof to a patient in need thereof having a body mass index (weight/height 2 ) in the range of 18-30 kg/m 2 .
  • the recombinant LAG-3 or derivatives thereof are administered in a free form, for example in a soluble form by inoculating them systemically, for example as a subcutaneous, intramuscular or intravenous injection, preferably as a subcutaneous injection.
  • Said recombinant LAG-3 or derivatives thereof may also be formulated so as to allow administration with a compound having anti-cancer or anti-infectious disease immunotherapeutical or chemotherapeutical properties.
  • administration with a compound in the sense of the present invention, is meant an administration of a recombinant LAG-3 or derivative thereof before, with, or subsequent to, the administration of said compound.
  • compound having anti-cancer or anti-infectious disease chemotherapeutical properties is meant for example a chemotherapy agent selected from the group consisting of taxanes (paclitaxel, docetaxel), gemcitabine and anthracyclines (doxorubicine) or an anti-viral agent such as ribavirin.
  • a chemotherapy agent selected from the group consisting of taxanes (paclitaxel, docetaxel), gemcitabine and anthracyclines (doxorubicine) or an anti-viral agent such as ribavirin.
  • recombinant LAG-3 protein or derivative thereof is administered to patients after the first administration of the cytotoxic compound having anti-cancer or anti-infectious disease chemotherapeutical properties.
  • recombinant LAG-3 protein or derivative thereof is administered to patients is administered 12 to 96 hours after the administration of the cytotoxic compound having anti-cancer or anti-infectious disease chemotherapeutical properties.
  • recombinant LAG-3 protein or derivative thereof is administered to patients is administered one or two days after the first administration of the compound having anti-cancer or anti-infectious disease chemotherapeutical properties.
  • recombinant LAG-3 protein or derivative and the cytotoxic compound having anti-cancer or anti-infectious disease chemotherapeutical properties are administered simultaneously, separately or sequentially.
  • recombinant LAG-3 protein or derivative thereof is administered at least six times, for example seven times, ten times, twelve times or more.
  • recombinant LAG-3 protein or derivative thereof is administered on an every-two-week schedule.
  • recombinant LAG-3 protein or derivative thereof is administered at a dose comprised between 0.25 to 30 mg, eventually at a dose comprised between 6 to 30 mg, eventually at a dose comprised between 8 to 25 mg, eventually between 12 and 20 mg.
  • compound having anti-cancer or anti-infectious disease immunotherapeutical properties is also meant for example a compound selected from the group consisting of therapeutic antibodies killing tumour cells through ADCC (antibody-dependent cell cytotoxicity), and mixtures thereof, and preferably from the group consisting of rituximab, cetuximab, edrecolomab, and trastuzumab.
  • ADCC antibody-dependent cell cytotoxicity
  • recombinant LAG-3 protein or derivative thereof and therapeutic antibodies are administered to patients simultaneously, separately or sequentially.
  • recombinant LAG-3 protein or derivative thereof is administered to patients the same day as therapeutic antibodies.
  • the present invention also relates to kit-of-parts, i.e. a combined preparation, containing recombinant LAG-3 protein or derivative thereof and a therapeutic antibody for simultaneous, separate or sequential use.
  • the kit-of-parts contains recombinant LAG-3 protein or derivative thereof and a therapeutic antibody selected from the group consisting of rituximab, cetuximab, edrecolomab, and trastuzumab.
  • the kit-of-part of the invention contain recombinant LAG-3 protein or derivative thereof and rituximab.
  • recombinant LAG-3 protein or derivative thereof and a therapeutic antibody form a functional unity, because of a synergistic cytotoxic effect between the two components.
  • This effect is a new joint effect, because the two components administered alone does not have the same effect as when administered as a combined preparation.
  • the present invention also relates to kit-of-parts, i.e. a combined preparation, containing recombinant LAG-3 protein or derivative thereof and a compound having anti-cancer or anti-infectious disease chemotherapeutical properties for simultaneous, separate or sequential use.
  • kit-of-parts i.e. a combined preparation, containing recombinant LAG-3 protein or derivative thereof and a compound having anti-cancer or anti-infectious disease chemotherapeutical properties for simultaneous, separate or sequential use.
  • the kit-of-parts contains recombinant LAG-3 protein or derivative thereof and a compound having anti-cancer or anti-infectious disease chemotherapeutical properties selected from the group consisting of taxanes (paclitaxel, docetaxel), gemcitabine and anthracyclines (doxorubicine).
  • a compound having anti-cancer or anti-infectious disease chemotherapeutical properties selected from the group consisting of taxanes (paclitaxel, docetaxel), gemcitabine and anthracyclines (doxorubicine).
  • the present invention also relates to a method for treating a pathological condition involving a monocyte mediated immune response, comprising administering the medicament as above defined to a patient in need thereof.
  • pathological condition involving a monocyte mediated immune response in the sense of the present invention, is meant viral infectious diseases, parasitic infectious diseases, bacterial infectious diseases, and cancer.
  • FIG. 1 represents fluorescence-activated cell sorting (FACS) analysis of monocytes (i.e. CD14 + CD45 + cells) in PBMCs from from metastatic breast carcinoma patients.
  • FACS fluorescence-activated cell sorting
  • FIG. 2 represents fluorescence-activated cell sorting (FACS) analysis of monocytes (i.e. CD14 + CD45 + cells) in fresh whole blood from metastatic breast carcinoma patients.
  • FACS fluorescence-activated cell sorting
  • FIG. 3 represents fluorescence-activated cell sorting (FACS) analysis of monocytes (i.e. CD14 + CD45 + cells) in fresh whole blood from metastatic renal cell cancer patients.
  • FACS fluorescence-activated cell sorting
  • FIG. 4 represents fluorescence-activated cell sorting (FACS) analysis of monocytes (i.e. CD14 + CD45 + cells) in fresh whole blood from metastatic breast carcinoma patients.
  • FACS fluorescence-activated cell sorting
  • FIG. 5 represents the pharmacokinetic profiles of IMP321 measured by ELISA in the plasma of metastatic renal cell cancer patients.
  • FIG. 6 represents the flow cytometry analysis of PBMC cultured in different conditions with rituximab and/or IMP321.
  • Example 1 Monocytes Increase in Metastatic Breast Cancer (MBC) Patients Using Low IMP321 Dose
  • PBMCs Blood samples were collected in heparinated lithium tubes (Vacutainer; BD Biosciences) from each patient, 14 days after the last IMP321 injection (i.e. looking at lasting immunomodulatory effects of the product), at 3 months (Day 85) and 6 months (Day 170).
  • PBMCs were isolated on Ficoll-Paque gradient (Pharmacia) using LeucoSep tubes (Greiner Bio-One), and used immediately.
  • the increase in number of monocytes was analysed by fluorescence-activated cell sorting (FACS) in said fresh PBMC samples (because monocytes are sensitive to freezing), and compared with the monocyte counts carried out on fresh PBMC samples collected before IMP321 administration (Day 1).
  • FACS fluorescence-activated cell sorting
  • results showed a 2.5-fold (at 3 months, Day 85) and a 3.5-fold (at 6 months, Day 170) mean increase of monocyte counts at this low IMP321 dose clinical protocol.
  • Example 2 Monocytes Increase in Metastatic Renal Clear-Cell Carcinoma (MRCC) Patients Using High IMP321 Dose
  • MRCC patients each received one subcutaneous IMP321 dose of 6.25 mg every other week, for 12 weeks, separated by 14-day administration-free intervals.
  • Blood samples were collected as described above from each patient, days after the last IMP321 injection (i.e. looking at lasting immunomodulatory effects of the product), at 2 months (Day 57) and 3 months (Day 85), and used immediately.
  • CD14 + CD45 + cells The expansion of CD14 + CD45 + cells was analysed by FACS in fresh blood samples (because monocytes are sensitive to freezing), and compared with the monocyte counts carried out on fresh blood samples collected before IMP321 administration (Day 1).
  • Example 3 Monocytes Increase in Metastatic Breast Carcinoma Patients Receiving Paclitaxel and IMP321 Doses
  • IMP321 was administered at days 3 or 17.
  • each patient received a standard 6-month course of weekly paclitaxel with 12 s.c. injections of IMP321, each injection being given one to two days after paclitaxel administration on an every-two-week schedule.
  • Example 4 Treatment of Advanced Pancreas Cancer Patients Receiving Gemcitabine and IMP321 Doses
  • IMP321 is administered at days 3 or 17.
  • each patient receives a standard 6-month course of gemcitabine with 12 s.c. injections of IMP321, each injection being given one to two days after gemcitabine administration on an every-two-week schedule.
  • the number of monocytes is analysed by fluorescence-activated cell sorting (FACS) as in example 1.
  • FACS fluorescence-activated cell sorting
  • PBMCs are first incubated for 40 hours with IL-2 (100 U/ml), with or without IMP321 (at the concentrations 0 ⁇ g/m, 0.03 ⁇ g/ml or 0.1 ⁇ g/ml). PBMCs are then incubated with increasing concentrations of rituximab (0, 0.5 and 5 ⁇ g/ml) in the presence of target cells (i.e. human CD20 + Raji B cells).
  • target cells i.e. human CD20 + Raji B cells.
  • Raji cells were first labeled with CFSE (carboxy-fluorescein succinimidyl ester), incubated in medium with rituximab at 0, 0.5 or 5 ⁇ g/ml and cocultured with effector cells at an effector-target ratio of 25:1 for 6 hours at 37° C.
  • CFSE carboxy-fluorescein succinimidyl ester
  • the cells were then incubated with 7-AAD (7-amino-actinomycin-D) for 15 min on ice and analyzed by flow cytometry to determine the percentage of dead CFSE + 7-AAD + Raji target cells (i.e. % of cytotoxicity).
  • IMP321 When 0.03 or 0.1 ⁇ g/ml IMP321 is added, the percentage of cytotoxicity greatly increased. For instance, a 30% cytotoxicity is observed with 0.5 ⁇ g/ml rituximab in the presence of 0.1 ⁇ g/ml IMP321 which is superior to the 25% cytotoxicity value obtained with 5 ⁇ g/ml rituximab in the absence of IMP321.
  • IMP321 potentializes 10-15 fold the activity of rituximab because a superior cytotoxicity is obtained with 10 time less antibody when a low dose IMP321 (0.1 ⁇ g/ml) is added.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.

Description

    TECHNICAL FIELD
  • The present invention relates to the use of recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response.
  • It enables an increase in monocyte numbers in blood.
  • It finds many applications in particular in the development of novel therapeutic agents in cancer immunotherapy.
  • In the description which follows, the references between brackets [ ] refer to the attached reference list.
    • STATE OF THE ART
  • The lymphocyte activation gene 3 (hlag-3) expressed in human CD4+ and CD8+ activated T cells as well as in activated NK cells encodes a 503 amino acids type I membrane protein (LAG-3) with four extracellular immunoglobulin superfamily (IgSF) domains [1]. A murine lymphocyte activation gene 3 (mlag-3) was cloned and approximately 70% of homology was found with hlag-3, with the same proline rich motif in the intracytoplasmic tail.
  • LAG-3 (CD223), described as being a natural high affinity ligand for MHC class II, is known to induce maturation of monocyte-derived dendritic cells in vitro, and is used as an immunotherapy adjuvant to induce CD4 T helper type 1 responses and CD8 T cell responses in vivo [2]. Further information regarding LAG-3 and its use as an immunostimulant may be found in TRIEBEL et al. [1], TRIEBEL et al. [3], and HUARD et al. [4].
  • Some forms of soluble LAG-3 can bind to MHC class II molecules and can induce dendritic cells to mature and migrate to secondary lymphoid organs where they can prime naïve CD4-helper and CD8-cytotoxic T cells leading to tumour rejection [5].
  • More recently a recombinant soluble human LAG-3Ig fusion protein (IMP321) was shown to activate a large range of effector cells in both innate and acquired immune responses, for example inducing monocytes-macrophages to secrete cytokines/chemokines [6].
  • Monocytes are produced by the bone marrow from haematopoietic stem cell precursors called monoblasts. They constitute between three to eight percent of the leukocytes in the blood. Monocytes circulate in the bloodstream for about 24 hours (half-life of 8 hours) and then typically move into tissues throughout the body. In the tissues, monocytes mature into macrophages, epithelioid cells or antigen-presenting cells (APCs, for example dendritic cells). Monocytes are responsible for phagocytosis (ingestion) of foreign substances in the body. Monocytes can perform phagocytosis using intermediary (opsonising) proteins such as antibodies or complement that coat the pathogen, as well as by binding to the pathogen directly via pattern-recognition receptors that recognize pathogens. Monocytes are also capable of killing infected host cells via antibody, termed antibody-dependent cell-mediated cytotoxicity (ADCC). Due to their secretion and phagocytosis properties, monocytes-macrophages occur in aspecific and specific immune response.
  • The study of membrane markers allows the identification of monocyte populations, mature or not, dystrophic or not. The molecules present on monocyte membranes, mature or not, are almost always non specific but correspond to the following activities:
      • receptor for the Fc fragment of IgG (CD16, CD32, CD64),
      • receptor for the Fe fragment of IgE (CD23),
      • receptor for complement fractions (CD11b, CD21/CD35),
      • leukocyte adhesion proteins (CD11a, CD11c),
      • protein facilitating binding to LPS of Gram − bacteria (CD14),
      • protein with tyrosine phosphatase activity (CD45).
    DISCLOSURE OF THE INVENTION
  • The authors of the present invention have now discovered, entirely unexpectedly, that human LAG-3 or derivatives thereof when inoculated into patients with highly malignant tumors, for example patients with metastatic breast cancer (MBC) or metastatic renal clear-cell carcinoma (MRCC), induced a potent immunity which is monocyte dependent.
  • Said induced immunity manifests itself by a significant increase in blood monocyte counts.
  • This result was achieved by means of plural administration of LAG-3 or derivatives thereof to patients receiving immunotherapy or chemo-immunotherapy.
  • This result is rather surprising since binding to, and activation of, monocytes is not expected to be followed by monocyte expansion. Indeed monocytes are end-of-differenciation hematopoietic cells and can not proliferate. They can stay in the blood as monocytes or differentiate toward either macrophages or dendritic cells under the influence of different cytokines, until they die. Thus it is believed, without limitation to the following theory, that the mechanism of action involved may be a proliferative signal directed to hematopoietic precursor cells (before the promonocyte stage) residing in the bone marrow, or an increase in the half-life or residence time of mature circulating monocytes.
  • Therefore the present invention relates to the use of a recombinant LAG-3 protein or derivative thereof that elicits monocyte mediated immune response, for the manufacture of a medicament inducing an increase in monocyte numbers for the treatment of an infectious disease or cancer.
  • By “derivatives of LAG-3”, in the sense of the present invention, is meant mutants, variants and fragments of LAG-3 provided that they maintain the ability of LAG-3 to bind MHC class II molecules.
  • Thus, the following forms of LAG-3 may be used:
      • the whole LAG-3 protein,
      • a soluble polypeptide fragment thereof consisting of at least one of the four immunoglobulin extracellular domains, namely the soluble part of LAG-3 comprised of the extracellular region stretching from the amino acid 23 to the amino acid 448 of the LAG-3 sequence disclosed in French patent Application FR 90 00 126,
      • a fragment of LAG-3 consisting of substantially all of the first and second domains,
      • a fragment of LAG-3 consisting of substantially all of the first and second domains or all of the four domains, such as defined in WO 95/30750,
      • a mutant form of soluble LAG-3 or a fragment thereof comprising the D1 and D2 extracellular domains and consisting of:
        • a substitution of an amino acid at one of the following positions:
      • position 73 where ARG is substituted with GLU,
      • position 75 where ARG is substituted with ALA or GLU,
      • position 76 where ARG is substituted with GLU,
      • or a combination of two or more of those substitutions,
        • a substitution of an amino acid at one of the following positions:
      • position 30 where ASP is substituted with ALA,
      • position 56 where HIS is substituted with ALA,
      • position 77 where TYR is substituted with PHE,
      • position 88 where ARG is substituted with ALA,
      • position 103 where ARG is substituted with ALA,
      • position 109 where ASP is substituted with GLU,
      • position 115 where ARG is substituted with ALA,
      • or a deletion of the region comprised between the position 54 and the position 66,
      • or a combination of two or more of those substitutions.
  • Those mutants are described by HUARD et al. (Proc. Natl. Acad. Sci. USA, 11: 5744-5749, 1997).
      • a physiological vaiant of LAG-3 comprised of the soluble 52 kDa protein containing D1, D2 and D3.
      • a recombinant soluble human LAG-3Ig fusion protein (IMP321), a 200-kDa dimer produced in Chinese hamster ovary cells transfected with a plasmid encoding for the extracellular domain of hLAG-3 fused to the human IgG1 Fc.
  • By «medicament», in the sense of the present invention, is meant an effective plurality of doses of a recombinant LAG-3 protein or derivative thereof.
  • By «effective plurality of doses of a recombinant LAG-3 protein or derivative thereof», in the sense of the present invention, is meant a formulation that allows administration of one dose of a recombinant LAG-3 protein or derivative thereof every one to several weeks for at least 12 weeks, and preferably for at least 24 weeks, separated by 13-day±2 days administration-free intervals. Advantageously, the administration is an every-two-week schedule.
  • By «one dose of a recombinant LAG-3 protein or derivative thereof», in the sense of the present invention, is meant a formulation that allows one administration in the range of 0.25-30 mg, preferably 1-6.25 mg, more preferably 6-30 mg, and for example about 1.25 mg of recombinant LAG-3 protein or derivative thereof to a patient in need thereof having a body mass index (weight/height2) in the range of 18-30 kg/m2.
  • The recombinant LAG-3 or derivatives thereof are administered in a free form, for example in a soluble form by inoculating them systemically, for example as a subcutaneous, intramuscular or intravenous injection, preferably as a subcutaneous injection.
  • Said recombinant LAG-3 or derivatives thereof may also be formulated so as to allow administration with a compound having anti-cancer or anti-infectious disease immunotherapeutical or chemotherapeutical properties.
  • By “administration with a compound”, in the sense of the present invention, is meant an administration of a recombinant LAG-3 or derivative thereof before, with, or subsequent to, the administration of said compound.
  • By “compound having anti-cancer or anti-infectious disease chemotherapeutical properties”, in the sense of the present invention, is meant for example a chemotherapy agent selected from the group consisting of taxanes (paclitaxel, docetaxel), gemcitabine and anthracyclines (doxorubicine) or an anti-viral agent such as ribavirin.
  • In a particular embodiment of the invention, recombinant LAG-3 protein or derivative thereof is administered to patients after the first administration of the cytotoxic compound having anti-cancer or anti-infectious disease chemotherapeutical properties.
  • Advantageously, recombinant LAG-3 protein or derivative thereof is administered to patients is administered 12 to 96 hours after the administration of the cytotoxic compound having anti-cancer or anti-infectious disease chemotherapeutical properties.
  • In another embodiment, recombinant LAG-3 protein or derivative thereof is administered to patients is administered one or two days after the first administration of the compound having anti-cancer or anti-infectious disease chemotherapeutical properties.
  • In another particular embodiment of the invention, recombinant LAG-3 protein or derivative and the cytotoxic compound having anti-cancer or anti-infectious disease chemotherapeutical properties are administered simultaneously, separately or sequentially.
  • Advantageously, in this particular embodiment of the invention, recombinant LAG-3 protein or derivative thereof is administered at least six times, for example seven times, ten times, twelve times or more.
  • Advantageously, in this particular embodiment of the invention, recombinant LAG-3 protein or derivative thereof is administered on an every-two-week schedule.
  • Advantageously, recombinant LAG-3 protein or derivative thereof is administered at a dose comprised between 0.25 to 30 mg, eventually at a dose comprised between 6 to 30 mg, eventually at a dose comprised between 8 to 25 mg, eventually between 12 and 20 mg.
  • By “compound having anti-cancer or anti-infectious disease immunotherapeutical properties”, in the sense of the present invention, is also meant for example a compound selected from the group consisting of therapeutic antibodies killing tumour cells through ADCC (antibody-dependent cell cytotoxicity), and mixtures thereof, and preferably from the group consisting of rituximab, cetuximab, edrecolomab, and trastuzumab.
  • In a particular embodiment of the invention, recombinant LAG-3 protein or derivative thereof and therapeutic antibodies are administered to patients simultaneously, separately or sequentially.
  • Advantageously, in a particular embodiment of the invention, recombinant LAG-3 protein or derivative thereof is administered to patients the same day as therapeutic antibodies.
  • The present invention also relates to kit-of-parts, i.e. a combined preparation, containing recombinant LAG-3 protein or derivative thereof and a therapeutic antibody for simultaneous, separate or sequential use.
  • Advantageously, the kit-of-parts contains recombinant LAG-3 protein or derivative thereof and a therapeutic antibody selected from the group consisting of rituximab, cetuximab, edrecolomab, and trastuzumab.
  • Preferentially, the kit-of-part of the invention contain recombinant LAG-3 protein or derivative thereof and rituximab.
  • In the kit-of-parts of the invention, recombinant LAG-3 protein or derivative thereof and a therapeutic antibody form a functional unity, because of a synergistic cytotoxic effect between the two components. This effect is a new joint effect, because the two components administered alone does not have the same effect as when administered as a combined preparation.
  • The present invention also relates to kit-of-parts, i.e. a combined preparation, containing recombinant LAG-3 protein or derivative thereof and a compound having anti-cancer or anti-infectious disease chemotherapeutical properties for simultaneous, separate or sequential use.
  • Advantageously, the kit-of-parts contains recombinant LAG-3 protein or derivative thereof and a compound having anti-cancer or anti-infectious disease chemotherapeutical properties selected from the group consisting of taxanes (paclitaxel, docetaxel), gemcitabine and anthracyclines (doxorubicine).
  • The present invention also relates to a method for treating a pathological condition involving a monocyte mediated immune response, comprising administering the medicament as above defined to a patient in need thereof.
  • By “pathological condition involving a monocyte mediated immune response”, in the sense of the present invention, is meant viral infectious diseases, parasitic infectious diseases, bacterial infectious diseases, and cancer.
  • Other advantages may also appear to one skilled in the art from the non-limitative examples given below, and illustrated by the enclosed figures.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 represents fluorescence-activated cell sorting (FACS) analysis of monocytes (i.e. CD14+CD45+ cells) in PBMCs from from metastatic breast carcinoma patients.
  • FIG. 2 represents fluorescence-activated cell sorting (FACS) analysis of monocytes (i.e. CD14+CD45+ cells) in fresh whole blood from metastatic breast carcinoma patients.
  • FIG. 3 represents fluorescence-activated cell sorting (FACS) analysis of monocytes (i.e. CD14+CD45+ cells) in fresh whole blood from metastatic renal cell cancer patients.
  • FIG. 4 represents fluorescence-activated cell sorting (FACS) analysis of monocytes (i.e. CD14+CD45+ cells) in fresh whole blood from metastatic breast carcinoma patients.
  • FIG. 5 represents the pharmacokinetic profiles of IMP321 measured by ELISA in the plasma of metastatic renal cell cancer patients.
  • FIG. 6 represents the flow cytometry analysis of PBMC cultured in different conditions with rituximab and/or IMP321.
    •  EXAMPLES Example 1: Monocytes Increase in Metastatic Breast Cancer (MBC) Patients Using Low IMP321 Dose
  • Five MBC patients, receiving chemotherapy known to induce tumour cell apoptosis, each received one subcutaneous IMP321 dose of 0.25 mg 1-2 days after chemotherapy every other week, for 24 weeks, separated by 14-day administration-free intervals.
  • Blood samples were collected in heparinated lithium tubes (Vacutainer; BD Biosciences) from each patient, 14 days after the last IMP321 injection (i.e. looking at lasting immunomodulatory effects of the product), at 3 months (Day 85) and 6 months (Day 170). PBMCs were isolated on Ficoll-Paque gradient (Pharmacia) using LeucoSep tubes (Greiner Bio-One), and used immediately.
  • The increase in number of monocytes was analysed by fluorescence-activated cell sorting (FACS) in said fresh PBMC samples (because monocytes are sensitive to freezing), and compared with the monocyte counts carried out on fresh PBMC samples collected before IMP321 administration (Day 1).
  • The results are represented in FIG. 1.
  • The results showed a 2.5-fold (at 3 months, Day 85) and a 3.5-fold (at 6 months, Day 170) mean increase of monocyte counts at this low IMP321 dose clinical protocol.
  • In order to confirm the above results, a more direct and probably more accurate approach was carried out, which was to quantify directly ex-vivo the number of monocytes in whole blood (i.e. without prior purification of PBMCs on Ficoll gradient) by first measuring the exact volume of blood to be analyzed with diluted fluorescent beads and then counting the number of CD14+ cells (i.e. monocytes) in the gated CD45+ (leukocytes) cells present in this whole blood volume.
  • The results are represented in FIG. 2.
  • The results showed a 4.4-fold mean increase at Day 170 (2.8-fold at Day 85) when IMP321 was given at low dose (0.25 mg) for a long period of time, 6 months, with 12 injections, showing strong and direct stimulation of the targeted MHC class II+ monocyte-like hematopoietic cells.
    • Example 2: Monocytes Increase in Metastatic Renal Clear-Cell Carcinoma (MRCC) Patients Using High IMP321 Dose
  • Three MRCC patients each received one subcutaneous IMP321 dose of 6.25 mg every other week, for 12 weeks, separated by 14-day administration-free intervals.
  • Blood samples were collected as described above from each patient, days after the last IMP321 injection (i.e. looking at lasting immunomodulatory effects of the product), at 2 months (Day 57) and 3 months (Day 85), and used immediately.
  • The expansion of CD14+ CD45+ cells was analysed by FACS in fresh blood samples (because monocytes are sensitive to freezing), and compared with the monocyte counts carried out on fresh blood samples collected before IMP321 administration (Day 1).
  • The results are represented in FIG. 3.
  • The results showed a 2-fold (at 3 months, Day 85) mean increase of monocyte counts with this high IMP321 dose clinical protocol where patients received only 6 injections.
    • Example 3: Monocytes Increase in Metastatic Breast Carcinoma Patients Receiving Paclitaxel and IMP321 Doses
  • Patients receiving as a first line chemotherapy for metastatic breast carcinoma 6 cycles of paclitaxel (80 mg/m2 given i.v.) on days 1, 8, and 15 of a 28 day cycle, received 1-30 mg s.c. (sub-cutaneous) IMP321 on days 2 and 16 of each 28-day cycle. Alternatively, IMP321 was administered at days 3 or 17.
  • Accordingly, each patient received a standard 6-month course of weekly paclitaxel with 12 s.c. injections of IMP321, each injection being given one to two days after paclitaxel administration on an every-two-week schedule.
  • The increase in absolute monocyte counts per microliter of fresh blood was analysed by fluorescence-activated cell sorting (FACS), 14 days after the last injection, at 3 months (Day 85) and 6 months (Day 170) compared to day 1.
  • The results obtained in patients injected with a low dose IMP321 (1.25 mg) are represented in FIG. 4.
  • These data showed that doses of 1.25 mg in most if not all patients (FIG. 4) induce an expansion of the monocyte subset pool in the blood.
  • It is predicted that the optimal dose regimen for IMP321 will be between 6 and 30 mg/injection.
  • These doses have been shown to be safe and give an acceptable systemic exposure based on the results of pharmacokinetics data obtained in metastatic renal cell cancer patients (FIG. 5). A blood concentration of IMP321 superior to 1 ng/ml for at least 24 hours after s.c. injection could be obtained in patients injected by IMP321 doses of more than 6 mg (FIG. 5).
    • Example 4: Treatment of Advanced Pancreas Cancer Patients Receiving Gemcitabine and IMP321 Doses
  • Patients, receiving as a first line chemotherapy for advanced pancreas cancer (or patients not eligible for surgical removal of the tumor) 6 cycles of standard gemcitabine (1 gm/m2 given i.v. over 30 min) on days 1, 8, and 15 of a 28 day cycle, receive in addition 6 to 30 mg s.c. IMP321 on days 2 and 16 of each 28-day cycle. Alternatively, IMP321 is administered at days 3 or 17.
  • Accordingly, each patient receives a standard 6-month course of gemcitabine with 12 s.c. injections of IMP321, each injection being given one to two days after gemcitabine administration on an every-two-week schedule.
  • The number of monocytes is analysed by fluorescence-activated cell sorting (FACS) as in example 1.
    • Example 5: Induction of Increased Rituximab-Mediated ADCC by Low Doses IMP321
  • PBMCs are first incubated for 40 hours with IL-2 (100 U/ml), with or without IMP321 (at the concentrations 0 μg/m, 0.03 μg/ml or 0.1 μg/ml). PBMCs are then incubated with increasing concentrations of rituximab (0, 0.5 and 5 μg/ml) in the presence of target cells (i.e. human CD20+ Raji B cells).
  • Raji cells were first labeled with CFSE (carboxy-fluorescein succinimidyl ester), incubated in medium with rituximab at 0, 0.5 or 5 μg/ml and cocultured with effector cells at an effector-target ratio of 25:1 for 6 hours at 37° C.
  • The cells were then incubated with 7-AAD (7-amino-actinomycin-D) for 15 min on ice and analyzed by flow cytometry to determine the percentage of dead CFSE+ 7-AAD+ Raji target cells (i.e. % of cytotoxicity).
  • The results are presented in FIG. 6.
  • Increasing the concentration of rituximab increased the percentage of cytotoxicity, clearly showing a dose-dependent ADCC activity.
  • When 0.03 or 0.1 μg/ml IMP321 is added, the percentage of cytotoxicity greatly increased. For instance, a 30% cytotoxicity is observed with 0.5 μg/ml rituximab in the presence of 0.1 μg/ml IMP321 which is superior to the 25% cytotoxicity value obtained with 5 μg/ml rituximab in the absence of IMP321.
  • Thus, adding 0.1 μg/ml IMP321 potentializes 10-15 fold the activity of rituximab because a superior cytotoxicity is obtained with 10 time less antibody when a low dose IMP321 (0.1 μg/ml) is added.
  • These data show the synergistic effect between rituximab and IMP321.
    • REFERENCE LIST
    • [1] TRIEBEL et al., J. Exp. Med., 171: 1393-1405, 1990
    • [2] BRIGNONE et al., J. Immune Based Ther Immunotherapies, 5: 5, 2007
    • [3] TRIEBEL et al., Trends Immunol., 24: 619-622, 2003
    • [4] HUARD et al., Proc. Natl. Acad. Sci. USA, 94: 5744-5749, 1997
    • [5] PRIGENT et al., Eur. J. Immunol., 29: 3867-3876, 1999
    • [6] BRIGNONE et al., J. Immunol., 179: 4202-4211, 2007

Claims (17)

1.-12. (canceled)
13. A kit-of-parts comprising recombinant human LAG-3 protein, or derivative thereof, and a chemotherapy agent, wherein the recombinant human LAG-3 protein comprises an extracellular region having the first, second, third and fourth immunoglobulin-like domains of a native human LAG-3 protein, and the derivative is selected from the group consisting of:
i) a fragment of the native human LAG-3 protein comprising the first and second immunoglobulin-like domains of the native human LAG-3 protein;
ii) a fragment of the native human LAG-3 protein comprising the first, second, third and fourth immunoglobulin-like domains of the native human LAG-3 protein;
iii) a mutant form of the native human LAG-3 protein, or a fragment thereof that comprises the first and second immunoglobulin-like domains of the native human LAG-3 protein, wherein the mutant comprises a substitution of an amino acid at one or more of the following positions:
a) position 73 where ARG is substituted with GLU,
b) position 75 where ARG is substituted with ALA or GLU,
c) position 76 where ARG is substituted with GLU,
iv) a variant of the native human LAG-3 protein comprising the first, second, and third immunoglobulin-like domains of the native human LAG-3 protein; and
v) a recombinant soluble human LAG-3Ig fusion protein (IMP321) comprising at least the first and second immunoglobulin-like domains of the native human LAG-3 protein fused to human IgG1 Fc.
14. The kit-of-parts of claim 13, wherein the kit-of-parts does not include any additional antigen.
15. The kit-of-parts of claim 13, wherein the recombinant human LAG-3 protein, or the derivative thereof, is provided as a dose of 1-30 mg of IMP321, or a molar equivalent of 1-30 mg of IMP321.
16. The kit-of-parts of claim 13, wherein the recombinant human LAG-3 protein, or derivative thereof, is provided as a dose of 6-30 mg of IMP321, or a molar equivalent of 6-30 mg of IMP321.
17. The kit-of-parts of claim 13, wherein the recombinant human LAG-3 protein, or derivative thereof, is provided as a dose of 8-25 mg of IMP321, or a molar equivalent of 8-25 mg of IMP321.
18. The kit-of-parts of claim 13, wherein the recombinant human LAG-3 protein, or derivative thereof, is provided as an effective plurality of doses of the recombinant human LAG-3 protein, or the derivative thereof.
19. The kit-of-parts of claim 18, wherein the effective plurality of doses includes at least six doses of the recombinant human LAG-3 protein, or derivative thereof.
20. The kit-of-parts of claim 18, wherein each dose of the effective plurality of doses of the recombinant human LAG-3 protein, or derivative thereof, is 1-30 mg of IMP321, or a molar equivalent of 1-30 mg of IMP321.
21. The kit-of-parts of claim 13, wherein the chemotherapy agent is provided as an effective plurality of doses.
22. The kit-of-parts of claim 13, wherein the recombinant human LAG-3 protein, or derivative thereof, and the chemotherapy agent, are each formulated for systemic administration.
23. The kit-of-parts of claim 13, wherein the recombinant human LAG-3 protein, or derivative thereof, and the chemotherapy agent, are each formulated for subcutaneous or intravenous administration.
24. The kit-of-parts of claim 13, wherein the chemotherapy agent is selected from the group consisting of taxanes, anthracyclines, and gemcitabine.
25. The kit-of-parts of claim 24, wherein the chemotherapy agent is a taxane.
26. The kit-of-parts of claim 25, wherein the chemotherapy agent is paclitaxel.
27. The kit-of-parts of claim 26, wherein the recombinant human LAG-3 protein, or derivative thereof, is IMP321.
28. A multiple-dose formulation which comprises an effective plurality of doses of a recombinant human LAG-3 protein, or derivative thereof, wherein the recombinant human LAG-3 protein comprises an extracellular region having the first, second, third and fourth immunoglobulin-like domains of a native human LAG-3 protein, and the derivative is selected from the group consisting of:
i) a fragment of the native human LAG-3 protein comprising the first and second immunoglobulin-like domains of the native human LAG-3 protein;
ii) a fragment of the native human LAG-3 protein comprising the first, second, third and fourth immunoglobulin-like domains of the native human LAG-3 protein;
iii) a mutant form of the native human LAG-3 protein, or a fragment thereof that comprises the first and second immunoglobulin-like domains of the native human LAG-3 protein, wherein the mutant comprises a substitution of an amino acid at one or more of the following positions:
a) position 73 where ARG is substituted with GLU,
b) position 75 where ARG is substituted with ALA or GLU,
c) position 76 where ARG is substituted with GLU,
iv) a variant of the native human LAG-3 protein comprising the first, second, and third immunoglobulin-like domains of the native human LAG-3 protein; and
v) a recombinant soluble human LAG-3Ig fusion protein (IMP321) comprising at least the first and second immunoglobulin-like domains of the native human LAG-3 protein fused to human IgG1 Fc.
US16/274,466 2007-10-05 2019-02-13 Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response Active 2029-01-13 US11583582B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/274,466 US11583582B2 (en) 2007-10-05 2019-02-13 Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
US18/098,199 US20230149541A1 (en) 2007-10-05 2023-01-18 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP07291214.0 2007-10-05
EP07291214 2007-10-05
EP07291214A EP2044949A1 (en) 2007-10-05 2007-10-05 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
PCT/IB2008/002653 WO2009044273A2 (en) 2007-10-05 2008-10-03 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US68106810A 2010-07-20 2010-07-20
US15/407,864 US10232038B2 (en) 2007-10-05 2017-01-17 Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
US16/274,466 US11583582B2 (en) 2007-10-05 2019-02-13 Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US15/407,864 Continuation US10232038B2 (en) 2007-10-05 2017-01-17 Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
US15/407,864 Division US10232038B2 (en) 2007-10-05 2017-01-17 Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/098,199 Continuation US20230149541A1 (en) 2007-10-05 2023-01-18 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response

Publications (2)

Publication Number Publication Date
US20190175726A1 true US20190175726A1 (en) 2019-06-13
US11583582B2 US11583582B2 (en) 2023-02-21

Family

ID=38871960

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/681,068 Active 2029-07-06 US9579382B2 (en) 2007-10-05 2008-10-03 Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
US15/407,864 Active US10232038B2 (en) 2007-10-05 2017-01-17 Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
US16/274,466 Active 2029-01-13 US11583582B2 (en) 2007-10-05 2019-02-13 Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
US18/098,199 Pending US20230149541A1 (en) 2007-10-05 2023-01-18 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/681,068 Active 2029-07-06 US9579382B2 (en) 2007-10-05 2008-10-03 Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
US15/407,864 Active US10232038B2 (en) 2007-10-05 2017-01-17 Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/098,199 Pending US20230149541A1 (en) 2007-10-05 2023-01-18 Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response

Country Status (12)

Country Link
US (4) US9579382B2 (en)
EP (7) EP2044949A1 (en)
JP (3) JP5908210B2 (en)
CN (3) CN101873864A (en)
AU (1) AU2008306576B2 (en)
DK (4) DK2601962T3 (en)
ES (4) ES2653615T3 (en)
NO (1) NO2604275T3 (en)
PL (3) PL2601961T3 (en)
PT (3) PT2601961T (en)
TR (1) TR201900764T4 (en)
WO (1) WO2009044273A2 (en)

Families Citing this family (294)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
ES2671748T3 (en) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
JP2016531907A (en) 2013-08-02 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Combination of CD27 agonist and immune checkpoint inhibition for immune stimulation
GB201322626D0 (en) * 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
DK3466949T3 (en) 2013-12-24 2021-03-15 Bristol Myers Squibb Co TRICYCLIC COMPOUND AS ANTICANCY AGENTS
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
EP3116909B1 (en) 2014-03-14 2019-11-13 Novartis Ag Antibody molecules to lag-3 and uses thereof
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
BR112016028255A2 (en) 2014-06-06 2017-08-22 Flexus Biosciences Inc immunoregulatory agents
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
UY36390A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JP2017538678A (en) 2014-11-05 2017-12-28 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． Immunomodulator
UY36391A (en) 2014-11-05 2016-06-01 Flexus Biosciences Inc MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO1), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR103232A1 (en) 2014-12-22 2017-04-26 Bristol Myers Squibb Co TGFbR ANTAGONISTS
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
MA41463A (en) * 2015-02-03 2017-12-12 Anaptysbio Inc ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3)
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
KR20170122799A (en) 2015-03-02 2017-11-06 리겔 파마슈티칼스, 인크. TGF-beta Inhibitor
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
PE20180117A1 (en) 2015-04-03 2018-01-18 Bristol Myers Squibb Co INDOLAMINE-2,3-DIOXYGENASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
CN114681608A (en) 2015-04-13 2022-07-01 戊瑞治疗有限公司 Combination cancer therapy
ES2905525T3 (en) 2015-05-06 2022-04-11 Snipr Tech Ltd Alteration of microbial populations and modification of the microbiota
US10683290B2 (en) 2015-05-11 2020-06-16 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
PE20180926A1 (en) 2015-05-29 2018-06-08 Bristol Myers Squibb Co ANTIBODIES AGAINST MEMBER 4 OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (OX40) AND ITS USES
MX2017015618A (en) 2015-06-03 2018-08-15 Boston Biomedical Inc Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer.
KR20180034548A (en) 2015-07-28 2018-04-04 브리스톨-마이어스 스큅 컴퍼니 TGF beta receptor antagonist
CN108349976A (en) 2015-08-25 2018-07-31 百时美施贵宝公司 Tgf beta receptor antagonists
EP3798234A1 (en) 2015-09-02 2021-03-31 Immutep S.A.S. Anti-lag-3 agonistic antibodies
US10265379B2 (en) * 2015-09-16 2019-04-23 Annabelle Rodriguez Oquendo Use of recombinant lymphocyte activation gene-3 as a companion therapeutic for patients at risk for cardiovascular disease and other chronic inflammatory diseases
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6936221B2 (en) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド CD80 extracellular domain polypeptides and their use in cancer treatment
CA3004530A1 (en) 2015-11-07 2017-05-11 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
RU2021107536A (en) 2015-11-23 2021-07-02 Файв Прайм Терапьютикс, Инк. FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN THE TREATMENT OF CANCER
JP6856648B2 (en) 2015-12-15 2021-04-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ CXCR4 receptor antagonist
RU2018123481A (en) 2015-12-16 2020-01-20 Мерк Шарп И Доум Корп. ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
US20190175748A1 (en) 2016-03-16 2019-06-13 Amal Therapeutics Sa Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine
EA201892362A1 (en) 2016-04-18 2019-04-30 Селлдекс Терапьютикс, Инк. AGONISTIC ANTIBODIES THAT ARE BINDING HUMAN CD40, AND THEIR OPTIONS
WO2017192815A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN109348714A (en) 2016-05-04 2019-02-15 百时美施贵宝公司 The inhibitor and its application method of indole amine 2,3-dioxygenase
WO2017192813A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN109414421A (en) 2016-05-04 2019-03-01 百时美施贵宝公司 The inhibitor and its application method of indole amine 2,3-dioxygenase
EP3452029A4 (en) 2016-05-04 2019-10-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
US11351164B2 (en) 2016-08-26 2022-06-07 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US20190255165A1 (en) 2016-09-21 2019-08-22 Amal Therapeutics Sa Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer
AU2017335732A1 (en) 2016-09-27 2019-04-04 Board Of Regents, The University Of Texas System Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
JP7041136B2 (en) 2016-10-12 2022-03-23 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Methods and Compositions for TUSC2 Immunotherapy
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
CN110381997A (en) 2016-12-12 2019-10-25 茂体外尔公司 For treating and preventing the method and composition comprising gene-virus therapy and immunologic test point inhibitor of cancer and infectious diseases
CN108204958A (en) * 2016-12-19 2018-06-26 伊缪泰普有限公司 binding assay
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
EP3570844B1 (en) 2017-01-20 2023-09-06 Arcus Biosciences, Inc. Azolopyrimidine for the treatment of cancer-related disorders
CA3057687A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
CN107129502B (en) 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315Mod.I crystal form compound and preparation method thereof
KR20190137911A (en) 2017-04-21 2019-12-11 신라젠(주) Anticancer Vaccinia Virus and Gateway Inhibitor Combination Therapy
MX2019012431A (en) 2017-04-21 2020-08-03 Ikena Oncology Inc Indole ahr inhibitors and uses thereof.
EP3628070B1 (en) 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP2020520923A (en) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド Methods for treating cancer
JP7189155B2 (en) 2017-05-17 2022-12-13 アーカス バイオサイエンシズ インコーポレイティド Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
WO2018219956A1 (en) 2017-05-29 2018-12-06 Gamamabs Pharma Cancer-associated immunosuppression inhibitor
MX2019012076A (en) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody.
AU2018277824A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
MX2019012038A (en) 2017-05-30 2019-11-18 Bristol Myers Squibb Co Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent.
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
JP2020524694A (en) 2017-06-22 2020-08-20 ノバルティス アーゲー IL-1β binding antibodies for use in the treatment of cancer
PE20200717A1 (en) 2017-06-22 2020-07-21 Novartis Ag ANTIBODY MOLECULES THAT BIND AND USES CD73
EP3645037A1 (en) 2017-06-27 2020-05-06 Novartis AG Dosage regimens for anti-tim-3 antibodies and uses thereof
IL271601B2 (en) 2017-06-30 2024-05-01 Bristol Myers Squibb Co Amorphous and crystalline forms of ido inhibitors
US20200172617A1 (en) 2017-07-20 2020-06-04 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
KR20200032180A (en) 2017-07-28 2020-03-25 브리스톨-마이어스 스큅 컴퍼니 Cyclic dinucleotide as an anticancer agent
KR20200051646A (en) 2017-08-17 2020-05-13 이케나 온콜로지, 인코포레이티드 AHR inhibitors and uses thereof
US10953032B2 (en) 2017-08-31 2021-03-23 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
US10947263B2 (en) 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7316263B2 (en) 2017-08-31 2023-07-27 ブリストル－マイヤーズ スクイブ カンパニー Cyclic dinucleotides as anticancer agents
JP7196160B2 (en) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
MX2020003190A (en) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Protein degraders and uses thereof.
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN111344297B (en) 2017-10-10 2023-10-20 百时美施贵宝公司 Cyclic dinucleotides as anticancer agents
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
KR20200065065A (en) 2017-10-16 2020-06-08 브리스톨-마이어스 스큅 컴퍼니 Cyclic dinucleotide as an anticancer agent
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag Antibodies targeting cd32b and methods of use thereof
KR20200074214A (en) 2017-11-01 2020-06-24 브리스톨-마이어스 스큅 컴퍼니 Anti-stimulatory antibody for use in treating cancer
JP7167146B2 (en) 2017-11-06 2022-11-08 ブリストル－マイヤーズ スクイブ カンパニー ISOFURANONE COMPOUNDS USEFUL AS HPK1 INHIBITORS
MX2020004756A (en) 2017-11-16 2020-08-20 Novartis Ag Combination therapies.
BR112020010579A2 (en) 2017-11-30 2020-11-10 Novartis Ag bcma targeting chimeric antigen receptor and uses thereof
JP2021508703A (en) 2017-12-26 2021-03-11 カイメラ セラピューティクス， インコーポレイテッド IRAK Degradants and Their Use
WO2019136112A1 (en) 2018-01-05 2019-07-11 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN112218651A (en) 2018-01-08 2021-01-12 诺华公司 Immunopotentiating RNA for combination with chimeric antigen receptor therapy
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
CN111886255A (en) 2018-01-12 2020-11-03 百时美施贵宝公司 anti-TIM 3 antibodies and uses thereof
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US10988477B2 (en) 2018-01-29 2021-04-27 Merck Patent Gmbh GCN2 inhibitors and uses thereof
TW201940481A (en) 2018-01-29 2019-10-16 美商維泰克斯製藥公司 GCN2 inhibitors and uses thereof
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
JP7250808B2 (en) 2018-03-08 2023-04-03 ブリストル－マイヤーズ スクイブ カンパニー Cyclic dinucleotides as anticancer agents
KR20200135986A (en) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 Methods and compositions for cancer treatment comprising tumor suppressor gene therapy and CD122/CD132 agonists
CN111971304A (en) 2018-03-21 2020-11-20 戊瑞治疗有限公司 Antibodies binding to VISTA at acidic pH
EP4066851A1 (en) 2018-03-25 2022-10-05 SNIPR Biome ApS. Treating & preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN112292128A (en) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 EP4 inhibitors and uses thereof
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
TW202015726A (en) 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
BR112020024351A2 (en) 2018-06-01 2021-02-23 Novartis Ag binding molecules against bcma and uses thereof
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
EP3814347B1 (en) 2018-06-27 2023-05-03 Bristol-Myers Squibb Company Naphthyridinone compounds useful as t cell activators
FI3814348T3 (en) 2018-06-27 2023-09-22 Bristol Myers Squibb Co Substituted naphthyridinone compounds useful as t cell activators
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
EP3820904A2 (en) 2018-07-09 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
CR20210001A (en) 2018-07-10 2021-04-19 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
JP2022513421A (en) 2018-07-11 2022-02-08 ファイブ プライム セラピューティクス， インコーポレイテッド Antibodies that bind VISTA at acidic pH
MX2021000745A (en) 2018-07-20 2021-03-26 Surface Oncology Inc Anti-cd112r compositions and methods.
US20210355113A1 (en) 2018-07-23 2021-11-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US20210299126A1 (en) 2018-07-23 2021-09-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
MX2021000726A (en) 2018-07-26 2021-03-25 Bristol Myers Squibb Co Lag-3 combination therapy for the treatment of cancer.
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN113164419A (en) 2018-09-07 2021-07-23 皮克医疗公司 EIF4E inhibitors and uses thereof
CN113164780A (en) 2018-10-10 2021-07-23 泰洛斯治疗公司 anti-LAP antibody variants and uses thereof
KR20210080437A (en) 2018-10-19 2021-06-30 브리스톨-마이어스 스큅 컴퍼니 Combination Therapy for Melanoma
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP3890749A4 (en) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
KR20210106437A (en) 2018-12-20 2021-08-30 노파르티스 아게 Dosage regimens and pharmaceutical combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2022516850A (en) 2018-12-21 2022-03-03 ノバルティス アーゲー Use of IL-1β antibody in the treatment or prevention of myelodysplastic syndrome
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
AU2019409139A1 (en) 2018-12-21 2021-06-03 Novartis Ag Use of IL-1β binding antibodies
KR20210146290A (en) 2019-02-12 2021-12-03 스미토모 다이니폰 파마 온콜로지, 인크. Formulations comprising heterocyclic protein kinase inhibitors
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020187998A1 (en) 2019-03-19 2020-09-24 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
AU2020253990A1 (en) 2019-04-02 2021-10-28 Bicycletx Limited Bicycle toxin conjugates and uses thereof
TW202106676A (en) 2019-04-05 2021-02-16 美商凱麥拉醫療公司 Stat degraders and uses thereof
GB201906118D0 (en) 2019-05-01 2019-06-12 Immutep S A Anti-LAG-3 binding molecules
US12012374B2 (en) 2019-05-13 2024-06-18 Bristol-Myers Squibb Company Agonists of ROR GAMMAt
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
CN114174538A (en) 2019-05-30 2022-03-11 百时美施贵宝公司 Multiple tumor gene signatures suitable for immunooncology therapy
KR20220016157A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Cell localization signatures and combination therapies
CN114502540A (en) 2019-05-31 2022-05-13 医肯纳肿瘤学公司 TEAD inhibitors and uses thereof
CN114302878A (en) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof
CN110320352A (en) * 2019-07-25 2019-10-11 上海轩锋生物科技有限公司 The antibody titer detection method of cell-mediated cyotoxicity based on antibody-dependant
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (en) 2019-08-28 2022-01-12 Bristol Myers Squibb Co SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS
WO2021050964A1 (en) 2019-09-13 2021-03-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN114502590A (en) 2019-09-18 2022-05-13 诺华股份有限公司 ENTPD2 antibodies, combination therapies, and methods of using these antibodies and combination therapies
JP2022548292A (en) 2019-09-19 2022-11-17 ブリストル－マイヤーズ スクイブ カンパニー Antibodies that bind VISTA at acidic pH
JP2022549273A (en) 2019-09-22 2022-11-24 ブリストル－マイヤーズ スクイブ カンパニー Quantitative spatial profiling for LAG-3 antagonist therapy
BR112022007376A2 (en) 2019-10-21 2022-07-05 Novartis Ag COMBINATION THERAPIES WITH VENETOCLAX AND TIM-3 INHIBITORS
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
KR20220093349A (en) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 LAG-3 antagonist therapy for melanoma
JP2023503052A (en) 2019-11-19 2023-01-26 ブリストル－マイヤーズ スクイブ カンパニー Compounds Useful as Inhibitors of Helios Protein
IL293357A (en) 2019-11-26 2022-07-01 Bristol Myers Squibb Co Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
EP4065582A1 (en) 2019-11-26 2022-10-05 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN110950966B (en) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 Fusion protein, encoding nucleic acid and cell and application
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11779578B2 (en) 2019-12-17 2023-10-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021123996A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
CA3162502A1 (en) 2019-12-23 2021-07-01 Yi Zhang Smarca degraders and uses thereof
IL294269A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinolinonyl piperazine compounds useful as t cell activators
BR112022012179A2 (en) 2019-12-23 2022-09-06 Bristol Myers Squibb Co SUBSTITUTED QUINAZOLINE COMPOUNDS USEFUL AS T-CELL ACTIVATORS
KR20220120624A (en) 2019-12-23 2022-08-30 브리스톨-마이어스 스큅 컴퍼니 Substituted piperazine derivatives useful as T cell activators
AR120823A1 (en) 2019-12-23 2022-03-23 Bristol Myers Squibb Co SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS
CN114846015A (en) 2019-12-23 2022-08-02 百时美施贵宝公司 Substituted heteroaryl compounds useful as T cell activators
EP4087874A1 (en) 2020-01-06 2022-11-16 HiFiBiO (HK) Limited Anti-tnfr2 antibody and uses thereof
MX2022008421A (en) 2020-01-07 2022-09-23 Hifibio Hk Ltd Anti-galectin-9 antibody and uses thereof.
AR121047A1 (en) 2020-01-15 2022-04-13 Blueprint Medicines Corp MAP4K1 INHIBITORS
JP2023510393A (en) 2020-01-17 2023-03-13 ノバルティス アーゲー A combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
JP2023514152A (en) 2020-02-06 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー IL-10 and its uses
KR20220164706A (en) 2020-03-03 2022-12-13 피아이씨 테라퓨틱스 인코포레이티드 EIF4E Inhibitors and Uses Thereof
MX2022011534A (en) 2020-03-19 2022-10-13 Arcus Biosciences Inc Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha.
JP2023518423A (en) 2020-03-19 2023-05-01 カイメラ セラピューティクス， インコーポレイテッド MDM2 degrading agents and their uses
TW202140441A (en) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 Substituted oxoisoindoline compounds
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
IL298507A (en) 2020-05-28 2023-01-01 Immutep Sas Treatment of cancer
JP2023528036A (en) 2020-06-02 2023-07-03 アーカス バイオサイエンシズ インコーポレイティド Antibody to TIGIT
WO2021245071A1 (en) 2020-06-03 2021-12-09 Mv Biotherapeutics Sa Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
TW202210483A (en) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Crystalline forms of irak degraders
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
CN115916199A (en) 2020-06-23 2023-04-04 诺华股份有限公司 Dosing regimens comprising 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
US11857535B2 (en) 2020-07-30 2024-01-02 Kymera Therapeutics, Inc. Methods of treating mutant lymphomas
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022033419A2 (en) 2020-08-10 2022-02-17 Shanghai Xbh Biotechnology Co., Ltd. Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
EP4196792A1 (en) 2020-08-17 2023-06-21 BicycleTX Limited Bicycle conjugates specific for nectin-4 and uses thereof
AU2021331476A1 (en) 2020-08-28 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
US20230303700A1 (en) 2020-08-31 2023-09-28 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
AU2021341521A1 (en) 2020-09-14 2023-03-30 Boehringer Ingelheim International Gmbh Heterologous prime boost vaccine
CA3198456A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
JP2023548051A (en) 2020-10-23 2023-11-15 ブリストル－マイヤーズ スクイブ カンパニー LAG-3 antagonist therapy for lung cancer
KR20230104651A (en) 2020-11-06 2023-07-10 노파르티스 아게 CD19 Binding Molecules and Uses Thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20230131189A (en) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 TEAD inhibitors and uses thereof
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
CN116964050A (en) 2020-12-16 2023-10-27 戈萨默生物服务公司 Compounds useful as T cell activators
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
EP4267105A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4274597A1 (en) 2021-01-11 2023-11-15 BicycleTX Limited Methods for treating cancer
US20230091528A1 (en) 2021-02-02 2023-03-23 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
AU2022216810A1 (en) 2021-02-02 2023-08-24 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
CR20230382A (en) 2021-02-12 2023-09-06 Hoffmann La Roche Bicyclic tetrahydroazepine derivatives for the treatment of cancer
AU2022220869A1 (en) 2021-02-15 2023-08-24 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
WO2022187856A1 (en) 2021-03-05 2022-09-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
WO2022192145A1 (en) 2021-03-08 2022-09-15 Blueprint Medicines Corporation Map4k1 inhibitors
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
IL307262A (en) 2021-03-29 2023-11-01 Juno Therapeutics Inc Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
IL307338A (en) 2021-04-05 2023-11-01 Bristol Myers Squibb Co Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
US11718601B2 (en) 2021-04-06 2023-08-08 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
TW202309022A (en) 2021-04-13 2023-03-01 美商努法倫特公司 Amino-substituted heterocycles for treating cancers with egfr mutations
JP2024514879A (en) 2021-04-16 2024-04-03 イケナ オンコロジー， インコーポレイテッド MEK inhibitors and their uses
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
AR125874A1 (en) 2021-05-18 2023-08-23 Novartis Ag COMBINATION THERAPIES
CN117337288A (en) 2021-05-21 2024-01-02 艾库斯生物科学有限公司 AXL inhibitor compounds
TW202313602A (en) 2021-05-21 2023-04-01 美商阿克思生物科學有限公司 Axl compounds
GB202108718D0 (en) 2021-06-18 2021-08-04 Immutep Sas Triple combination therapy
WO2023285552A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
AR126442A1 (en) 2021-07-14 2023-10-11 Blueprint Medicines Corp MAP4K1 INHIBITORS
CN117940406A (en) 2021-07-15 2024-04-26 缆图药品公司 MAP4K1 inhibitors
US20230134932A1 (en) 2021-08-25 2023-05-04 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2023028235A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
CA3224890A1 (en) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
US20230159466A1 (en) 2021-10-29 2023-05-25 Arcus Biosciences, Inc. Inhibitors of hif-2alpha and methods of use thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023147371A1 (en) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
WO2023150186A1 (en) 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023152335A1 (en) 2022-02-11 2023-08-17 Immutep S.A.S. Treatment of cancer
WO2023164638A1 (en) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
TW202404581A (en) 2022-05-25 2024-02-01 美商醫肯納腫瘤學公司 Mek inhibitors and uses thereof
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
US20240124490A1 (en) 2022-07-15 2024-04-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
WO2024020034A1 (en) 2022-07-20 2024-01-25 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024028365A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Substituted pyridone gpr84 antagonists and uses thereof
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024028363A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
WO2024036100A1 (en) 2022-08-08 2024-02-15 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
WO2024033389A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033388A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024033457A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydrothiazepine derivatives
WO2024059142A1 (en) 2022-09-14 2024-03-21 Arcus Biosciences, Inc. Dispersions of etrumadenant
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
WO2024086718A1 (en) 2022-10-20 2024-04-25 Arcus Biosciences, Inc. Lyophilized formulations of cd73 compounds
WO2024116140A1 (en) 2022-12-01 2024-06-06 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341281C (en) 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
AU642403B2 (en) * 1989-02-17 1993-10-21 Coselco Mimotopes Pty Ltd Method for the use and synthesis of peptides
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (en) 1990-01-08 1992-05-15 Roussy Inst Gustave NEW PROTEINS PRODUCED BY HUMAN LYMPHOCYTES, DNA SEQUENCE ENCODING THESE PROTEINS AND PHARMACEUTICAL AND BIOLOGICAL APPLICATIONS.
US7294712B2 (en) 1990-06-04 2007-11-13 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US6596536B1 (en) 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
CA2079879C (en) 1991-02-08 2007-11-06 Thierry Hercend Nucleotidic sequences coding for alpha chain variable regions in human lymphocite receptors and applications thereof
CA2079881C (en) 1991-02-12 2007-11-06 Thierry Hercend Nucleotidic sequences coding for variable regions of .beta. chains of human t lymphocite receptors, corresponding peptidic segments and diagnostic and therapeutic applications
DK0758383T3 (en) 1994-05-06 2007-05-29 Roussy Inst Gustave Soluble polypeptide fractions of the LAG-3 protein; method of manufacture; therapeutic composition; anti-idiotypic antibody
AU6267896A (en) * 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6277368B1 (en) * 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
CA2273080C (en) * 1996-11-28 2004-11-09 Institut Gustave Roussy Mutants of the lag-3 proteins, products for the expression of these mutants and use
IL130168A (en) * 1996-11-29 2006-09-05 Serono Lab Genetically engineered cells comprising dna expressing lag-3 and their use
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
FR2777890B1 (en) 1998-04-22 2000-12-29 Roussy Inst Gustave HSP70 PEPTIDE COMPOUNDS USEFUL IN CANCER IMMUNOTHERAPY
FR2795415B1 (en) 1999-06-28 2003-09-05 Roussy Inst Gustave PEPTIDE COMPOUND DERIVED FROM AN OFFSET ORF OF THE ICE GENE
AT409086B (en) * 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie NEW USE OF ANTIBODIES AS VACCINE
EP1276468A1 (en) 2000-04-26 2003-01-22 Biovector Therapeutics S.A. Use of particulate vectors in immunomodulation
DK1294401T3 (en) * 2000-06-29 2007-10-08 Merck Patent Gmbh Improvement of antibody / cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake preparations
EP1295895B1 (en) 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
JP2007508319A (en) * 2003-10-10 2007-04-05 パウダージェクト ワクチンズ，インコーポレーテッド Method
FR2868781B1 (en) 2004-04-13 2008-02-22 Immutep VACCINE COMPOSITION COMPRISING ANTIGEN-COUPLED CLAY II MHC LIGAND, METHOD OF PREPARATION AND USES
JP2006124383A (en) 2004-09-30 2006-05-18 Kobayashi Pharmaceut Co Ltd Dendritic cell activator
JP2006141346A (en) 2004-11-24 2006-06-08 Kobayashi Pharmaceut Co Ltd Dendritic cell activator
JP2009504787A (en) * 2005-08-19 2009-02-05 シーラス コーポレイション Enhanced immune response mediated by antibodies
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
US8425897B2 (en) 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN104470949A (en) 2012-05-15 2015-03-25 百时美施贵宝公司 Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Also Published As

Publication number Publication date
US20230149541A1 (en) 2023-05-18
PT2601962T (en) 2019-12-02
ES2705901T3 (en) 2019-03-27
JP2016074740A (en) 2016-05-12
EP2205257B8 (en) 2014-01-08
EP2205257A2 (en) 2010-07-14
EP2601961A1 (en) 2013-06-12
DK2604275T3 (en) 2018-02-26
US20110008331A1 (en) 2011-01-13
CN114159548A (en) 2022-03-11
EP2792365A1 (en) 2014-10-22
NO2604275T3 (en) 2018-04-21
CN105816855B (en) 2021-10-29
WO2009044273A3 (en) 2009-09-24
WO2009044273A2 (en) 2009-04-09
TR201900764T4 (en) 2019-02-21
DK2601961T3 (en) 2019-03-04
CN105816855A (en) 2016-08-03
EP2604275A1 (en) 2013-06-19
JP2010540616A (en) 2010-12-24
ES2437333T3 (en) 2014-01-10
EP2601962A1 (en) 2013-06-12
EP2205257B1 (en) 2013-09-11
US20170119876A1 (en) 2017-05-04
JP2014037436A (en) 2014-02-27
US9579382B2 (en) 2017-02-28
DK2205257T3 (en) 2013-12-02
PL2601961T3 (en) 2019-05-31
JP6169734B2 (en) 2017-07-26
EP2044949A1 (en) 2009-04-08
US11583582B2 (en) 2023-02-21
PL2601962T3 (en) 2020-02-28
ES2653615T3 (en) 2018-02-08
EP2601961B1 (en) 2018-11-28
EP2601962B1 (en) 2019-08-21
EP2604275B1 (en) 2017-11-22
JP5908210B2 (en) 2016-04-26
EP3586863A1 (en) 2020-01-01
ES2744700T3 (en) 2020-02-26
DK2601962T3 (en) 2019-11-25
AU2008306576A1 (en) 2009-04-09
PT2601961T (en) 2019-02-06
CN101873864A (en) 2010-10-27
PT2604275T (en) 2018-02-07
US10232038B2 (en) 2019-03-19
PL2604275T3 (en) 2018-09-28
AU2008306576B2 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
US11583582B2 (en) Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response
US11897937B2 (en) SIRPalpha-41BBL fusion protein and methods of use thereof
US10196435B2 (en) OX40L fusion protein for the immunotherapy of tumors of veterinary animals
JP2018529753A (en) Methods and compositions for the treatment of metastatic and refractory cancers and tumors
JP6682438B2 (en) Improved cell compositions and methods for cancer treatment
JP2002523378A (en) Activation and protection of T-cells (CD4 + and CD8 +) using H2-receptor agonists and other T-cell activating agents
KR20160093076A (en) Combined preparations for the treatment of cancer
DK3102151T3 (en) PROCEDURE FOR DETERMINING INTRAOCULAR LENS POWER
US20160008435A1 (en) Composition for preventing or treating b-cell lymphoma comprising il-21 expressing mesenchymal stem cells
CA2965848A1 (en) Phorbol ester compositions and methods for treating or reducing the duration of cytopenia
US20220119523A1 (en) Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
EP1367393A1 (en) Methods for using the CD 163 pathway for modulating an immune response
WO2017205779A2 (en) Compositions and methods for treating disorders related to inflammasome activity and il-1alpha expression
KR20220071892A (en) Novel anti-C-MPL antibodies and uses thereof
KR20110100861A (en) A composition for maturation of dendritic cell containing oncostatin m

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STCF Information on status: patent grant

Free format text: PATENTED CASE